Full View

Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - The …, 2015 - academic.oup.com
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
被引用次数：28 相关文章

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - …, 2015 - search.ebscohost.com
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer

B Halmos, NA Pennell, P Fu, S Saad… - …, 2015 - einstein.elsevierpure.com
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
isclearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
[HTML] nih.gov

[HTML][HTML] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - The …, 2015 - ncbi.nlm.nih.gov
Background. Epidermal growth factor receptor (EGFR) tyrosine kinaseinhibitor (TKI)
therapyisclearlybeneficialinpatientswith advanced EGFR-mutated non-small cell lung …

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer

B Halmos, NA Pennell, P Fu, S Saad… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer

B Halmos, NA Pennell, P Fu, S Saad… - …, 2015 - ohiostate.elsevierpure.com
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
isclearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - The …, 2015 - europepmc.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
[PDF] wiley.com

[PDF][PDF] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer

B Halmos, NA Pennell, P Fu, S Saad… - The …, 2015 - Wiley Online Library
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR‐mutated non‐small cell lung cancer …

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - The Oncologist, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background.</jats: title>< jats: p>
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is clearly …

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

B Halmos, NA Pennell, P Fu, S Saad, S Gadgeel… - The …, 2015 - europepmc.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …